The urothelium is the epithelial lining of the urinary tract, including the bladder and ureters.
译文：尿路上皮是尿道的上皮内衬，包括膀胱和输尿管。
Urothelial carcinoma is the most common type of bladder cancer.
译文：尿路上皮癌是最常见的膀胱癌类型。
Inflammation of the urothelium can cause symptoms such as frequent urination and pain.
译文：尿路上皮的炎症可能会导致诸如频尿和疼痛等症状。
Cystoscopy allows for direct visualization of the urothelium in the urinary bladder.
译文：膀胱镜检查可以直接观察到膀胱内的尿路上皮。
The
urothelial cells are capable of remarkable regenerative capacity after injury.
译文：尿路上皮细胞在受损后具有显著的再生能力。
Hyperplasia of the urothelium may be a precancerous condition.
译文：尿路上皮增生可能是癌前病变。
Urothelial dysfunction can lead to urinary incontinence or retention issues.
译文：尿路上皮功能障碍可能导致尿失禁或排尿困难问题。
A thorough understanding of
urothelial biology is essential for developing new therapies for urological diseases.
译文：深入理解尿路上皮生物学对于研发治疗泌尿系统疾病的新疗法至关重要。
Biomarkers found in urine can indicate damage to the urothelium.
译文：尿液中发现的生物标志物可能表明尿路上皮受到了损害。
Chronic irritation of the urothelium increases the risk of developing
urothelial tumors.
译文：尿路上皮的慢性刺激会增加患上尿路上皮肿瘤的风险。
The partnership with the local diagnostic company will further empower full-cycle patient management in various ways, including fast reimbursement to optimize the diagnosis of Janssen's target therapeutic areas such as lung cancer and urothelial cancer.
与当地诊断公司的合作将以各种方式进一步增强全周期患者管理能力，包括快速报销，以优化杨森目标治疗领域的诊断，如肺癌癌症和尿路上皮癌症。
A supporting tumor gene detection kit for the system has also been successfully developed, which can be adapted to many types of samples from tissues to body fluids, including glioma, lung, urothelial, breast and thyroid cancers, covering the fields of early screening, molecular pathology diagnosis and medication guidance, the company said.
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
在4月，中国国家药品监督管理局批准了该公司的抗PD-1抗体tislelizumab用于治疗局部晚期或转移性尿路上皮癌（最常见的膀胱癌）的患者，此前该疗法于2019年12月首次被批准用于经典霍奇金淋巴瘤。
Tislelizumab received approval from the China National Medical Products Administration last April as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December 2019.
China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.
The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.
未经许可，严禁转发。QQ交流群：688169419